4.7 Article

Long-Term Prognosis After Coronary Artery Calcification Testing in Asymptomatic Patients A Cohort Study

期刊

ANNALS OF INTERNAL MEDICINE
卷 163, 期 1, 页码 14-21

出版社

AMER COLL PHYSICIANS
DOI: 10.7326/M14-0612

关键词

-

资金

  1. U.S. Food and Drug Administration/National Institutes of Health
  2. American Heart Association
  3. Aetna
  4. Pfizer
  5. Luitpold Pharmaceuticals
  6. General Electric Healthcare
  7. National Heart, Lung, and Blood Institute
  8. National Research Foundation of Korea

向作者/读者索取更多资源

Background: The extent of coronary artery calcification (CAC) and near-term adverse clinical outcomes are strongly related through 5 years of follow-up. Objective: To describe the ability of CAC scores to predict long-term mortality in persons without symptoms of coronary artery disease. Design: Observational cohort. Setting: Single-center, outpatient cardiology laboratory. Patients: 9715 asymptomatic patients. Measurements: Coronary artery calcification scoring and binary risk factor data were collected. The primary end point was time to all-cause mortality (median follow-up, 14.6 years). Univariable and multivariable Cox proportional hazards models were used to compare survival distributions. The net reclassification improvement statistic was calculated. Results: In Cox models adjusted for risk factors for coronary artery disease, the CAC score was highly predictive of all-cause mortality (P < 0.001). Overall 15-year mortality rates ranged from 3% to 28% for CAC scores from 0 to 1000 or greater (P < 0.001). The relative hazard for all-cause mortality ranged from 1.68 for a CAC score of 1 to 10 (P < 0.001) to 6.26 for a score of 1000 or greater (P < 0.001). The categorical net reclassification improvement using cut points of less than 7.5% to 22.5% or greater was 0.21 (95% Cl, 0.16 to 0.32). Limitations: Data collection was limited to a single center with generalizability limitations. Only binary risk factor data were available, and CAC was only measured once. Conclusion: The extent of CAC accurately predicts 15-year mortality in a large cohort of asymptomatic patients. Long-term estimates of mortality provide a unique opportunity to examine the value of novel biomarkers, such as CAC, in estimating important patient outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据